Article Contents ::
- 1 The Brand Name PETIN Has Generic Salt :: Paroxetine
- 2 PETIN Is From Company MOLEKULE Priced :: Rs. 160
- 3 PETIN have Paroxetine is comes under Sub class Anti Depressants of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PETIN Has Generic Salt :: Paroxetine
PETIN Is From Company MOLEKULE Priced :: Rs. 160
PETIN have Paroxetine is comes under Sub class Anti Depressants of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Paroxetine||CR TAB||Rs. 160||10|
Indications for Drugs ::
Depression, Anxiety, Panic disorder, Obsessive-compulsive disorder, Posttraumatic stress disorder, Social anxiety disorder, Premenstrual dysmorphic disorder
Drug Dose ::
Adult: PO Depression Initial: 20 mg/day. May increase if needed. Max: 50 mg/day. Obsessive-compulsive disorder Initial: 20 mg/day. May increase if needed. Maintenance: 40-60 mg/day. Panic disorder Initial: 10 mg. May increase if needed. Maintenance: 40-60 mg/day. Social anxiety disorder Initial: 20 mg/day. May increase if needed. Max: 50-60 mg/day. Anxiety; Posttraumatic stress disorder Initial: 20 mg/day. May increase if needed. Max: 50 mg/day. Premenstrual dysmorphic disorder As HCI: Extended release Initial: 12.5 mg once daily. May increase if needed. Take throughout menstrual cycle or limited to the luteal phase.
Use with or within 14 days of MAOIs; concurrent use with thioridazine or pimozide.
Drug Precautions ::
Epilepsy, glaucoma, history of mania, cardiac disease, DM, history of bleeding disorders, on drugs with increased risk of bleeding; renal and hepatic impairment; patients receiving electroconvulsive therapy; achlorhydria or high gastric pH (reduced absorption of oral suspension). Pregnancy and lactation. The risk of suicidal behaviour may be higher in young adults, closely monitor. May impair ability to drive or perform tasks. Avoid abrupt withdrawal.
Drug Side Effects ::
Somnolence, insomnia, headache, dizziness; decreased libido; nausea, xerostomia, constipation, diarrhoea; ejaculatory disturbances; weakness, tremor, diaphoresis; vasodilation, chest pain, palpitation, hypertension, tachycardia, nervousness, anxiety , agitation, abnormal dreams, impaired concentration, yawning, depersonalisation, amnesia, emotional lability, vertigo, confusion, chills; rash, pruritus; orgasmic disturbance, dysmenorrhoea; anorexia, decreased appetite, dyspepsia, flatulence, abdominal pain, appetite increased, vomiting, taste perversion, weight gain; impotence, genital disorder, urinary frequency, UTI; paresthesia, myalgia, back pain, myoclonus, myopathy, myasthenia, arthralgia; blurred vision, abnormal vision; tinnitus; respiratory disorder, pharyngitis, sinusitis, rhinitis; infection.
Pregnancy category ::
Drug Mode of Action ::
Paroxetine selectively inhibits the reuptake of serotonin. It has limited direct action at other neurotransmitter sites including muscarinic receptors.
Drug Interactions ::
Levels/effects inhibited by cyproheptadine, phenytoin. Levels/effects increased by carbamazepine, cimetidine, CYP2D6 inhibitors (e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, pergolide, quinidine, quinine, ritonavir, ropinirole). Increases levels/effects of atomoxetine, carvedilol, clozapine, CYP2B6 substrates (e.g. bupropion, promethazine, propofol, selegiline, sertraline), CYP2D6 substrates (e.g. amphetamines, selected beta-blockers, dextromethorphan, fluoxetine, lidocaine, mirtazapine, nefazodone, risperidone, ritonavir, thioridazine, TCAs, venlafaxine), duloxetine, galantamine, mexilitine, pimozide, procyclidine, propafenone. Decreases levels/effects of CYP2D6 prodrug substrates (e.g. codeine, hydrocodone, oxycodone, tramadol). Inhibits the metabolism of dextromethorphan, haloperidol, thioridazine. Enhances bradycardic effect of beta-blockers. Enhances toxic effects of other CNS depressants. Increased risk of serotonin syndrome with amphetamines, SSRIs, meperidine, nefazodone, trazodone, serotonin agonists, sibutramine, sympathomimetics, tramadol, venlafaxine. Increases risk of bleeding with NSAIDs, aspirin, warfarin, or other drugs affecting coagulation. Increases sensitivity to amphetamines. Neurotoxicity with lithium. Additive hyponatraemia with loop diuretics. Mania or hypertension with selegiline. Potentially Fatal: Fatal reactions with nonselective MAOI.